Aurobindo Pharma Ltd
About
Aurobindo Pharma is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialisation of generic pharmaceuticals, injectables, and active pharmaceutical ingredients (APIs). The company, currently headquartered in Hyderabad, was founded by P.V. Ramprasad Reddy and Mr. K. Nityananda Reddy in 1986 with just a single unit, the semi-synthetic penicillin. Today, the company provides solutions to oncology, vaccines, peptides, dermatology, respiration, hormones, biosimilars, injectables, and more in over 150 countries. Aurobindo owns 5 R&D facilities in India and 4 in the USA, and more than 29 manufacturing and packaging facilities internationally. The company is approved by regulatory agencies in countries like Japan, South Africa, Brazil, Canada, the US, and the UK.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 30505 19.4% | 25556 10.8% | 23075 -20.8% | 29135 24.6% | 23392 14.7% | 20397 19.6% | 17051 11.2% | 15340 8.9% | 14093 12.3% | 12547 52.6% | 8223 33.6% | 6154 32.1% | 4658 0.0% | 4659 19.0% | 3914 22.4% | 3199 - |
| Net Operating Income (INR Cr) | 29002 16.68% | 24855 5.97% | 23455 -5.32% | 24775 7.26% | 23099 18.07% | 19564 18.83% | 16463 10.42% | 14910 8.08% | 13795 13.81% | 12121 49.64% | 8100 38.33% | 5855 26.54% | 4627 5.61% | 4381 24.34% | 3524 15.99% | 3038 25.22% |
| Profit (INR Cr) | 3173 64.6% | 1928 -27.2% | 2648 -50.4% | 5335 87.5% | 2845 20.3% | 2365 -2.4% | 2423 5.3% | 2302 13.7% | 2025 28.5% | 1576 34.4% | 1173 299.1% | 294 - | -124 - | 563 0.0% | 563 461.9% | 100 - |
| Assets (INR Cr) | 36776 13.7% | 32352 17.1% | 27638 0.4% | 27519 20.6% | 22813 9.0% | 20939 26.8% | 16519 29.3% | 12777 3.4% | 12354 27.9% | 9657 27.8% | 7554 24.6% | 6061 11.2% | 5450 11.9% | 4871 22.2% | 3988 11.5% | 3577 - |
| Net Worth (INR Cr) | 29843 11.2% | 26840 9.2% | 24576 12.1% | 21930 30.3% | 16825 21.1% | 13891 18.9% | 11680 24.6% | 9372 28.6% | 7287 41.3% | 5156 37.5% | 3750 43.9% | 2606 11.4% | 2340 -4.3% | 2445 33.7% | 1829 47.4% | 1241 10.4% |
| Employee Cost (INR Cr) | 3923 11.4% | 3522 2.1% | 3451 -2.4% | 3535 9.8% | 3219 24.5% | 2585 21.3% | 2131 20.5% | 1768 14.6% | 1543 18.5% | 1302 62.3% | 802 21.0% | 663 23.8% | 536 26.0% | 425 29.9% | 327 34.3% | 244 - |
| Interest Cost (INR Cr) | 290 | 140 | 49 | 74 | 305 | 263 | 78 | 67 | 257 | 160 | 310 | 267 | 277 | 65 | 73 | 93 |
| Cash & Bank Balance (INR Cr) | 6278 | 6084 | 4190 | 5474 | 2842 | 1957 | 1262 | 513 | 800 | 469 | 179 | 208 | 71 | 187 | 73 | 128 |
| Total Debt (INR Cr) | 6648 | 5286 | 2851 | 5339 | 5826 | 6967 | 4770 | 3364 | 5041 | 4451 | 3769 | 3435 | 3096 | 2414 | 2155 | 2333 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 10.4% | 7.5% | 11.5% | 18.3% | 12.2% | 11.6% | 14.2% | 15.0% | 14.4% | 12.6% | 14.3% | 4.8% | - | 12.1% | 14.4% | 3.1% |
| Profit As % Of Assets | 8.6% | 6.0% | 9.6% | 19.4% | 12.5% | 11.3% | 14.7% | 18.0% | 16.4% | 16.3% | 15.5% | 4.9% | - | 11.6% | 14.1% | 2.8% |
| Profit As % Of Networth | 10.6% | 7.2% | 10.8% | 24.3% | 16.9% | 17.0% | 20.8% | 24.6% | 27.8% | 30.6% | 31.3% | 11.3% | - | 23.1% | 30.8% | 8.1% |
| Interest Cost to EBITDA % | 5.1% | 3.8% | 1.2% | 1.5% | 6.3% | 6.8% | 2.1% | 1.9% | 8.1% | 6.2% | 14.5% | 31.0% | 115.5% | 6.8% | 9.5% | 54.0% |
| Debt to Equity Ratio | 0.22 | 0.20 | 0.12 | 0.24 | 0.35 | 0.50 | 0.41 | 0.36 | 0.69 | 0.86 | 1.01 | 1.32 | 1.32 | 0.99 | 1.18 | 1.88 |
| RONW | 11.2% | 7.5% | 11.4% | 17.6% | 18.5% | 18.5% | 23.0% | 27.6% | 32.5% | 35.3% | 36.7% | 11.7% | - | 26.3% | 36.6% | 5.1% |
| ROCE | 13.5% | 9.2% | 12.4% | 18.3% | 18.5% | 17.9% | 22.7% | 24.9% | 27.3% | 27.1% | 27.1% | 11.1% | 7.5% | 19.3% | 21.9% | 4.9% |